Quotes 5-day view Delayed Nasdaq Stockholm
06/17/2022
06/20/2022
06/21/2022
06/22/2022
06/23/2022
Date
211.1(c)
213.6(c)
214.9(c)
217.2(c)
217.3(c)
Last
1 452 892
231 482
789 722
672 890
362 533
Volume
+2.03%
+1.18%
+0.61%
+1.07%
+0.05%
Change
Estimated financial data (e) SEK USD
Sales 2022
17 499 M
1 728 M
1 728 M
Net income 2022
2 342 M
231 M
231 M
Net Debt 2022
6 507 M
643 M
643 M
P/E ratio 2022
28,1x
Yield 2022
-
Sales 2023
18 710 M
1 848 M
1 848 M
Net income 2023
3 285 M
324 M
324 M
Net Debt 2023
2 124 M
210 M
210 M
P/E ratio 2023
19,6x
Yield 2023
-
Capitalization
64 137 M
6 334 M
6 334 M
EV / Sales 2022
4,04x
EV / Sales 2023
3,54x
Nbr of Employees
1 569
Free-Float
57,8%
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the...
Ratings of Swedish Orphan Biovitrum AB (publ)
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
News in other languages on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short Term Mid-Term Long Term Trends Neutral Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
8
Last Close Price
217,30 SEK
Average target price
245,38 SEK
Spread / Average Target
12,9%
Please enable JavaScript in your browser's settings to use dynamic charts.